Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association.
More than 1.2 million percutaneous coronary interventions are performed annually in the United States, with only an estimated 33% performed in women, despite the established benefits of percutaneous coronary intervention and adjunctive pharmacotherapy in reducing fatal and nonfatal ischemic complications in acute myocardial infarction and high-risk acute coronary syndromes. This statement reviews sex-specific data on the safety and efficacy of contemporary interventional therapies in women.
Lansky
Alexandra J
AJ
Hochman
Judith S
JS
Ward
Patricia A
PA
Mintz
Gary S
GS
Fabunmi
Rosalind
R
Berger
Peter B
PB
New
Gishel
G
Grines
Cindy L
CL
Pietras
Cody G
CG
Kern
Morton J
MJ
Ferrell
Margaret
M
Leon
Martin B
MB
Mehran
Roxana
R
White
Christopher
C
Mieres
Jennifer H
JH
Moses
Jeffrey W
JW
Stone
Gregg W
GW
Jacobs
Alice K
AK
D015906:Angioplasty, Balloon, Coronary / Q000379:methods* / Q000401:mortality / Q000706:statistics & numerical data; D003327:Coronary Disease / Q000401:mortality / Q000628:therapy*; D004358:Drug Therapy / Q000379:methods* / Q000706:statistics & numerical data; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012737:Sex Factors; D015607:Stents / Q000009:adverse effects; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors